Characterization of C4-2 prostate cancer bone metastases and their response to castration

被引:35
作者
Pfitzenmaier, J
Quinn, JE
Odman, AM
Zhang, JA
Keller, ET
Vessella, RL
Corey, E
机构
[1] Univ Washington, Dept Urol, Seattle, WA 98195 USA
[2] Univ Mainz, Dept Urol, D-6500 Mainz, Germany
[3] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA
关键词
prostatic neoplasm; bone; metastasis; models; animal; prostate specific antigen;
D O I
10.1359/jbmr.2003.18.10.1882
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
New well-characterized preclinical models of prostate cancer (CaP) bone metastases are needed to improve our understanding of the development of CaP-related bone disease in patients. Here we describe characterization of a model consisting of direct injection of C4-2 cells into tibias. Introduction: Prostate cancer (CaP) has a high proclivity to metastasize to bone. Development and characterization of preclinical models of CaP bone metastases are of high interest. The objective of this study was to characterize C4-2 bone metastases and their response to castration. Materials and Methods: Cell suspensions of C4-2, a subline of LNCaP, were injected directly into the tibias of intact male mice. In groups A (n = 7) and B (n = 5), animals were killed 3 and 8 weeks after injection of C4-2 cells, respectively. In group C (n = 7), animals were castrated 3 weeks after injection and killed 5 weeks after castration. Serum prostate-specific antigen (PSA) levels and bone mineral density (BMD) were measured, and bone histomorphometric analysis was performed. Results: C4-2 cells decreased BMD of the injected tibias by 36.1% and bone volume by 74.1% versus normal tibias. Castration caused a 32.3% drop in serum PSA (p = 0.0438), with a nadir at day 14, after which it began to rise again. Bone destruction in the tumorous tibias of castrated animals was decreased by 15.9% versus tumorous tibias of intact animals (p = 0.0392). However, BMD in the tumorous tibias of castrated mice was still lower than in normal tibias of intact animals. Castration also decreased BMD and bone volume in nontumorous tibias (p = 0.0406 and 0.0232, respectively). Conclusions: The C4-2 model of bone metastasis recapitulates the response to androgen deprivation observed in CaP patients with bone metastases and is suitable for study of interactions between tumor and bone cells and evaluation of new therapeutic modalities.
引用
收藏
页码:1882 / 1888
页数:7
相关论文
共 19 条
[1]  
BERLIN O, 1993, CANCER RES, V53, P4890
[2]   Establishment and characterization of osseous prostate cancer models: Intra tibial injection of human prostate cancer cells [J].
Corey, E ;
Quinn, JE ;
Bladou, F ;
Brown, LG ;
Roudier, MP ;
Brown, JM ;
Buhler, KR ;
Vessella, RL .
PROSTATE, 2002, 52 (01) :20-33
[3]   Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer [J].
Harris, KA ;
Weinberg, V ;
Bok, RA ;
Kakefuda, M ;
Small, EJ .
JOURNAL OF UROLOGY, 2002, 168 (02) :542-545
[4]   Cancer statistics, 2002 [J].
Jemal, A ;
Thomas, A ;
Murray, T ;
Thun, M .
CA-A CANCER JOURNAL FOR CLINICIANS, 2002, 52 (01) :23-47
[5]   Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice [J].
Klein, KA ;
Reiter, RE ;
Redula, J ;
Morad, H ;
Zhu, XL ;
Brothman, AR ;
Lamb, DJ ;
Marcelli, M ;
Belldegrun, A ;
Witte, ON ;
Sawyers, CL .
NATURE MEDICINE, 1997, 3 (04) :402-408
[6]  
Nemeth JA, 1999, CANCER RES, V59, P1987
[7]   Skeletal fracture associated with androgen suppression induced osteoporosis: The clinical incidence and risk factors for patients with prostate cancer [J].
Oefelein, MG ;
Ricchuiti, V ;
Conrad, W ;
Seftel, A ;
Bodner, D ;
Goldman, H ;
Resnick, M .
JOURNAL OF UROLOGY, 2001, 166 (05) :1724-1728
[8]   Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era [J].
Oefelein, MG ;
Ricchiuti, VS ;
Conrad, PW ;
Goldman, H ;
Bodner, D ;
Resnick, MI ;
Seftel, A .
UROLOGY, 2002, 60 (01) :120-124
[9]   Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy [J].
Rigaud, J ;
Tiguert, R ;
Le Normand, L ;
Karam, G ;
Glemain, P ;
Buzelin, JM ;
Bouchot, O .
JOURNAL OF UROLOGY, 2002, 168 (04) :1423-1426
[10]  
Roudier MP, 2000, J BONE MINER RES, V15, pS567